{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004161","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2022-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.400180+00:00","generated_at":"2026-06-26T21:46:43.051622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Janux reports FY2021 net loss $32.7M; cash $375M; IND filings for two TRACTr programs on track for 2022","bullets":["Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.","Net loss $13.4M for Q4 2021 and $32.7M for FY2021; R&D expense $26.2M (FY2021).","PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.","Nominated first TRACIr candidate, a PD-L1xCD28 costimulatory bispecific; IND planned for 2023.","Appointed Byron Robinson, Ph.D., J.D., as Chief Strategy Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004161","json":"https://secwatch.observer/filing/0000950170-22-004161.json","markdown":"https://secwatch.observer/filing/0000950170-22-004161.md","text":"https://secwatch.observer/filing/0000950170-22-004161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022004161/0000950170-22-004161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017022004161/janx-20220318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:46:43.051622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}